// App-Quantinova.ai

873 : A novel MET-EGFR bispecific antibody LY3164530 shows advantage over combining MET and EGFR antibodies in tumor inhibition and overcome resistance

Researchers

Presenter

  • Ling Liu

Principal Investigators

  • Wei Zeng

  • Marcio Chedid

  • Yi Zeng

  • Sheng-hung Tschang

  • Yu Tian

  • Ying Tang

  • Jirong Lu

Medical Centers

  • Eli Lilly and Company, Indianapolis, IN

  • Eli Lilly and Company, San Diego, CA

Locations

  • United States

Companies

  • Eli Lilly and Compan

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • LY3164530

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved